GIA
NVNO

Gladstone Institutional Advisory’s enVVeno Medical NVNO Stock Holding History

Gladstone Institutional Advisory’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-46
Closed -$17K – 314
2020
Q3 		$17K Hold
46
– – ﹤0.01% 267
2020
Q2 		$15K Hold
46
– – ﹤0.01% 241
2020
Q1 		$12K Buy
46
+12
+35% +$5.69K ﹤0.01% 266
2019
Q4 		$17K Buy
34
+11
+48% +$5.7K ﹤0.01% 271
2019
Q3 		$17K Buy
+23
New +$20K ﹤0.01% 281

Other funds holding NVNO

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Gladstone Institutional Advisory's NVNO Position: Q4 2020 in Review

Gladstone Institutional Advisory sold out of enVVeno Medical (NVNO) in Q4 2020, closing a stake of 46 shares — an estimated $17K sold.

Gladstone Institutional Advisory first reported a position in NVNO in Q3 2019 and held it in 5 quarters. The position peaked at $17K in Q3 2020. 7 funds tracked by Wall St. Rank hold NVNO as of Q4 2020.

  • Gladstone Institutional Advisory reported no remaining enVVeno Medical position as of Q4 2020 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 46 enVVeno Medical shares in Q4 2020, an estimated $17K.
  • Gladstone Institutional Advisory first reported a position in enVVeno Medical in Q3 2019 and held it in 5 quarters.
  • Gladstone Institutional Advisory's enVVeno Medical position peaked at $17K in Q3 2020.
  • 7 funds tracked by Wall St. Rank held enVVeno Medical as of Q4 2020.

Based on Gladstone Institutional Advisory's 13F filing for Q4 2020, filed 16 Feb 2021.